ALIBABA-GROUP
11.6.2019 06:02:07 CEST | Business Wire | Press release
Alibaba A.I. Labs, an AI research division of Alibaba Group, today announced at CES Asia partnerships with auto brands, including Audi, Renault and Honda to drive a smart mobility initiative in China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190610005833/en/
Tmall Genie Auto, an Artificial Intelligence solution developed by Alibaba A.I. Labs, will be integrated into the automakers’ specific internet cars in China.
Owners of the three auto brands’ specific-model vehicles equipped with Tmall Genie Auto will have access to a wide variety of voice-controlled information and services in the near future; these include identifying nearby attractions and restaurants, booking movie tickets, ordering to-go boxes, checking the status of package deliveries, reading children’s books and ordering items on Alibaba’s retail platform.
In addition, car owners with a Tmall Genie-compatible device at home would be able to monitor and control their smart-home devices from their cars in the near future, performing daily tasks such as running a status check on temperature and light, or turning on the heater and air conditioning at home.
“By providing AI technologies, including speech-recognition and Natural Language Processing, Tmall Genie Auto enables car users to access an extensive in-car infotainment portfolio by tapping into Alibaba’s rich content and service ecosystem,” said Miffy Chen, General Manager at Alibaba A.I. Labs . “We are thrilled to partner with global distinguished auto brands such as Audi, Renault and Honda. Together, we can greatly enhance our in-car services and make driving experience more intelligent and interconnected.”
“We aim to extend in-car voice assistant services according to the demands and needs of our Chinese customers,” said H.W. Vassen, Senior Director of Digitalization and NEV Development at Audi China . “To do so, one of our next steps is to intensity the cooperation with Alibaba Tmall Genie.”
Guillaume SICARD, Vice President of Sales and Marketing, Region China, Groupe Renault , commented: “The launch of the Renault City K-ZE Tmall Genie Edition allows consumers to experience a deeper connection between scenarios in their lives at home and their lives on the go. It is also a manifesto that DRAC and Tmall will continue to maintain profound cooperation on areas such as brand marketing, potential customer mining and sales network enablement, in order to achieve new breakthroughs.”
Hasegawa Yusuke, the Executive Vice President of Honda Motor (China) Investment Co., Ltd , said: “The world’s mobility industries are currently undergoing a major transformation. Our mobility and daily lives will finally enter into the era of Internet for Everything, Honda has been actively embracing the trend of electrification and ICVs, and accelerating the advancement of the third-generation Honda CONNECT system which includes the Smart AI function. We look forward to working with Alibaba A.I. Labs on creative initiatives by leveraging the AI technology and Alibaba’s diverse ecosystem services.”
During CES Asia, Alibaba’s B2C marketplace Tmall also announced its tie-up with Renault to roll out an electric car featuring Tmall’s iconic cat logo on the vehicle’s exterior design. The Renault City K-ZE genie edition, also integrated with Tmall Genie Auto, will be on sale in China later this year.
Tmall Genie is the bestselling smart speaker in China. Today it can control over 100 million devices from over 600 smart appliance brands, offering its Internet of Things ecosystem capabilities to various sectors and user environments from home, car, hotels to nursing homes.
Alibaba A.I. Labs spearheads consumer AI product development at Alibaba Group. Since the launch of Tmall Genie Auto solution last April, Alibaba A.I. Labs has also partnered with auto brands including BMW and Volvo Cars to provide intelligent and connected mobility experiences for consumers in China.
About Alibaba A.I. Labs
Alibaba A.I. Labs is dedicated to exploring the next-generation human-and-computer interaction and turning novel user experience into reality. The in-house R&D department focuses on the development of innovative AI applications across Alibaba’s commerce ecosystem and provides AI solutions to Alibaba’s clients and partners. With a world-class research team, Alibaba A.I. Labs focuses on both theoretical research and product commercialization in various areas, including speech recognition, natural language processing, voice print identification, deep learning, and computer vision. The Labs also focuses on developing AI products for consumers, including Tmall Genie, the first voice- controlled smart home assistant developed by the Labs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005833/en/
Contact:
Crystal Liu Alibaba Group +86 18578497650/+852 6378 5626 Crystal.liu@alibaba-inc.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom